ANEBULO PHARMACEUTICALS INC (ANEB) Stock Fundamental Analysis

NASDAQ:ANEB • US0345691036

0.36 USD
-0.07 (-16.49%)
At close: Feb 27, 2026
0.382 USD
+0.02 (+6.11%)
After Hours: 2/27/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, ANEB scores 2 out of 10 in our fundamental rating. ANEB was compared to 193 industry peers in the Pharmaceuticals industry. The financial health of ANEB is average, but there are quite some concerns on its profitability. ANEB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ANEB had negative earnings in the past year.
  • In the past year ANEB has reported a negative cash flow from operations.
  • ANEB had negative earnings in each of the past 5 years.
  • In the past 5 years ANEB always reported negative operating cash flow.
ANEB Yearly Net Income VS EBIT VS OCF VS FCFANEB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • ANEB has a worse Return On Assets (-84.68%) than 75.13% of its industry peers.
  • The Return On Equity of ANEB (-100.53%) is worse than 62.18% of its industry peers.
Industry RankSector Rank
ROA -84.68%
ROE -100.53%
ROIC N/A
ROA(3y)-123.91%
ROA(5y)-118.64%
ROE(3y)-132.86%
ROE(5y)-124.7%
ROIC(3y)N/A
ROIC(5y)N/A
ANEB Yearly ROA, ROE, ROICANEB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ANEB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANEB Yearly Profit, Operating, Gross MarginsANEB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • ANEB has more shares outstanding than it did 1 year ago.
  • ANEB has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for ANEB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANEB Yearly Shares OutstandingANEB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
ANEB Yearly Total Debt VS Total AssetsANEB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of -7.82, we must say that ANEB is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -7.82, ANEB is not doing good in the industry: 65.80% of the companies in the same industry are doing better.
  • ANEB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.82
ROIC/WACCN/A
WACCN/A
ANEB Yearly LT Debt VS Equity VS FCFANEB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 10M 20M

2.3 Liquidity

  • A Current Ratio of 6.24 indicates that ANEB has no problem at all paying its short term obligations.
  • The Current ratio of ANEB (6.24) is better than 69.95% of its industry peers.
  • ANEB has a Quick Ratio of 6.24. This indicates that ANEB is financially healthy and has no problem in meeting its short term obligations.
  • ANEB's Quick ratio of 6.24 is fine compared to the rest of the industry. ANEB outperforms 70.47% of its industry peers.
Industry RankSector Rank
Current Ratio 6.24
Quick Ratio 6.24
ANEB Yearly Current Assets VS Current LiabilitesANEB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 32.14% over the past year.
EPS 1Y (TTM)32.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 65.24% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-88.31%
EPS Next 2Y-34.34%
EPS Next 3Y-24.34%
EPS Next 5Y65.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANEB Yearly Revenue VS EstimatesANEB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2031 2032 2033 50M 100M
ANEB Yearly EPS VS EstimatesANEB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ANEB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANEB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANEB Price Earnings VS Forward Price EarningsANEB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANEB Per share dataANEB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

  • ANEB's earnings are expected to decrease with -24.34% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.34%
EPS Next 3Y-24.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ANEB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ANEBULO PHARMACEUTICALS INC

NASDAQ:ANEB (2/27/2026, 8:00:00 PM)

After market: 0.382 +0.02 (+6.11%)

0.36

-0.07 (-16.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-12
Earnings (Next)05-11
Inst Owners54.08%
Inst Owner Change-0.05%
Ins Owners40.54%
Ins Owner Change0%
Market Cap14.79M
Revenue(TTM)N/A
Net Income(TTM)-7.98M
Analysts43.33
Price Target8.16 (2166.67%)
Short Float %0.21%
Short Ratio0.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)60.72%
Min EPS beat(2)59.15%
Max EPS beat(2)62.29%
EPS beat(4)4
Avg EPS beat(4)45.43%
Min EPS beat(4)21.57%
Max EPS beat(4)62.29%
EPS beat(8)6
Avg EPS beat(8)28.4%
EPS beat(12)9
Avg EPS beat(12)23.17%
EPS beat(16)9
Avg EPS beat(16)9.63%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.86
P/tB 1.86
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -84.68%
ROE -100.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-123.91%
ROA(5y)-118.64%
ROE(3y)-132.86%
ROE(5y)-124.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.24
Quick Ratio 6.24
Altman-Z -7.82
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.44%
EPS Next Y-88.31%
EPS Next 2Y-34.34%
EPS Next 3Y-24.34%
EPS Next 5Y65.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-13.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.04%
OCF growth 3YN/A
OCF growth 5YN/A

ANEBULO PHARMACEUTICALS INC / ANEB FAQ

What is the ChartMill fundamental rating of ANEBULO PHARMACEUTICALS INC (ANEB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ANEB.


Can you provide the valuation status for ANEBULO PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to ANEBULO PHARMACEUTICALS INC (ANEB). This can be considered as Overvalued.


What is the profitability of ANEB stock?

ANEBULO PHARMACEUTICALS INC (ANEB) has a profitability rating of 0 / 10.


How financially healthy is ANEBULO PHARMACEUTICALS INC?

The financial health rating of ANEBULO PHARMACEUTICALS INC (ANEB) is 6 / 10.